AU8756691A - Compositions and methods for inhibiting growth or replication of viruses - Google Patents

Compositions and methods for inhibiting growth or replication of viruses

Info

Publication number
AU8756691A
AU8756691A AU87566/91A AU8756691A AU8756691A AU 8756691 A AU8756691 A AU 8756691A AU 87566/91 A AU87566/91 A AU 87566/91A AU 8756691 A AU8756691 A AU 8756691A AU 8756691 A AU8756691 A AU 8756691A
Authority
AU
Australia
Prior art keywords
oligonucleotides
oligonucleotide
hybridizable
alkyl
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU87566/91A
Other languages
English (en)
Inventor
Laure Aurelian
Paul O.P. Ts'o
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of AU8756691A publication Critical patent/AU8756691A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU87566/91A 1990-09-21 1991-09-18 Compositions and methods for inhibiting growth or replication of viruses Abandoned AU8756691A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58618590A 1990-09-21 1990-09-21
US586185 1990-09-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU24910/95A Division AU2491095A (en) 1990-09-21 1995-07-07 Compositions and methods for inhibiting growth or replication of viruses

Publications (1)

Publication Number Publication Date
AU8756691A true AU8756691A (en) 1992-04-15

Family

ID=24344663

Family Applications (2)

Application Number Title Priority Date Filing Date
AU87566/91A Abandoned AU8756691A (en) 1990-09-21 1991-09-18 Compositions and methods for inhibiting growth or replication of viruses
AU24910/95A Abandoned AU2491095A (en) 1990-09-21 1995-07-07 Compositions and methods for inhibiting growth or replication of viruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU24910/95A Abandoned AU2491095A (en) 1990-09-21 1995-07-07 Compositions and methods for inhibiting growth or replication of viruses

Country Status (8)

Country Link
EP (1) EP0656942A1 (fr)
JP (1) JPH06501162A (fr)
AU (2) AU8756691A (fr)
CA (1) CA2092711A1 (fr)
IE (1) IE913321A1 (fr)
IL (1) IL99543A0 (fr)
NZ (1) NZ239883A (fr)
WO (1) WO1992005284A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003051A1 (fr) * 1990-08-15 1992-03-05 Genta Incorporated Inhibition de l'infection provoquee par le virus de l'herpes, a l'aide d'oligonucleotides non codants
WO1994001551A1 (fr) * 1992-07-02 1994-01-20 United States Of America, Represented By The Secretary, Department Of Health And Human Services Procede d'inhibition de la replication virale
CA2105595A1 (fr) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Polynucleotides antisens
FR2708270B1 (fr) * 1993-07-28 1995-10-20 Genset Sa Oligonucléotides antisens dirigés contre les virus Herpès Simplex de types 1 & 2.
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
WO1995032986A1 (fr) * 1994-06-01 1995-12-07 Hybridon, Inc. Oligonucleotides ramifies inhibiteurs des agents pathogenes
US7176303B2 (en) * 2003-11-06 2007-02-13 Isis Pharmaceuticals, Inc. Modulation of STAT5 expression
WO2024113302A1 (fr) * 2022-12-01 2024-06-06 深圳先进技术研究院 Arng ciblant des gènes essentiels du hsv, système d'édition de gène crispr/cas, système d'administration et utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
AU636573B2 (en) * 1988-02-26 1993-05-06 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers

Also Published As

Publication number Publication date
NZ239883A (en) 1993-10-26
IE913321A1 (en) 1992-02-25
EP0656942A1 (fr) 1995-06-14
CA2092711A1 (fr) 1992-03-22
AU2491095A (en) 1995-11-02
WO1992005284A1 (fr) 1992-04-02
EP0656942A4 (fr) 1998-04-15
JPH06501162A (ja) 1994-02-10
IL99543A0 (en) 1992-08-18

Similar Documents

Publication Publication Date Title
Zabolotny et al. The herpes simplex virus type 1 2.0-kilobase latency-associated transcript is a stable intron which branches at a guanosine
US6265167B1 (en) Targeted RNA degradation using nuclear ribozyme RNA
Ambinder et al. Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA
Boldogh et al. Transcriptional activation of cellular oncogenes fos, jun, and myc by human cytomegalovirus
JP5010466B2 (ja) Ｄｎａウイルスのマイクロｒｎａ及びそれを阻害する医薬品
US6150339A (en) Anti-viral guanosine-rich oligonucleotides
AU678628B2 (en) Oligonucleotide modulation of multidrug resistance-associated protein
US5442049A (en) Oligonucleotides for modulating the effects of cytomegalovirus infections
US20060183231A1 (en) Multiple-compartment eukaryotic expression systems
AU2003202376A1 (en) Oligonucleotides comprising alternating segments and uses thereof
JPH02276577A (ja) ＨＩＶ　Ｉからのトランスアクチベーター標的配列（ＴＡＲ）およびトランスアクチベータータンパク質（Ｔａｔ）の合成の阻害のためのアンチセンスオリゴヌクレオチド類およびそれらの使用
AU662040B2 (en) Pseudorabies virus (PRV) polynucleotides and their use for preparing virus-resistant eukaryotic cells
AU8756691A (en) Compositions and methods for inhibiting growth or replication of viruses
US7704965B2 (en) Methods and materials for treating human papillomavirus infections
US5990298A (en) CIS-acting cellular nucleic acid molecules
AU698089B2 (en) Oligonucleotides with anti-cytomegalovirus activity
US5550047A (en) Oligonucleotides with anti-Epstein-Barr virus activity
Adami et al. The length but not the sequence of the polyoma virus late leader exon is important for both late RNA splicing and stability
CA2211877A1 (fr) Inhibiteurs de la transcription du virus de l'immunodeficience humaine et procedes pour les utiliser
US5837854A (en) Oligonucleotides with anti-Epstein-Barr virus activity
NZ239372A (en) Inhibition of herpes virus infection by antisense oligomers
Remenick et al. Inhibition of adenovirus DNA replication by vesicular stomatitis virus leader RNA
US7227012B1 (en) Latency-associated regulatory region from Herpesvirus saimiri (HVS)
US5807838A (en) Oligonucleotide modulation of multidrug resistance-associated protein
JP2024520524A (ja) 短鎖相補的核酸、短鎖相補的核酸を含む組成物、および抗ウイルス剤としての使用のための方法